TY - JOUR
T1 - Reply
AU - Kalligeros, Markos
AU - Mylonakis, Eleftherios
AU - Noureddin, Mazen
PY - 2024/8
Y1 - 2024/8
N2 - We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States. 1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et al 2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.
AB - We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States. 1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et al 2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.
UR - http://www.scopus.com/inward/record.url?scp=85188431227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85188431227&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2024.01.036
DO - 10.1016/j.cgh.2024.01.036
M3 - Letter
C2 - 38346568
AN - SCOPUS:85188431227
SN - 1542-3565
VL - 22
SP - 1752
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 8
ER -